Jordi Rio

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9358280/publications.pdf

Version: 2024-02-01

121	6,318	66234	74018
papers	citations	42 h-index	75 g-index

132	132	132	5645
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Defining high, medium and low impact prognostic factors for developing multiple sclerosis. Brain, 2015, 138, 1863-1874.	3.7	403
2	Defining the response to interferonâ€Î² in relapsingâ€remitting multiple sclerosis patients. Annals of Neurology, 2006, 59, 344-352.	2.8	295
3	Does the Modified Fatigue Impact Scale offer a more comprehensive assessment of fatigue in MS?. Multiple Sclerosis Journal, 2005, 11, 198-202.	1.4	243
4	Scoring treatment response in patients with relapsing multiple sclerosis. Multiple Sclerosis Journal, 2013, 19, 605-612.	1.4	227
5	Measures in the first year of therapy predict the response to interferon Î² in MS. Multiple Sclerosis Journal, 2009, 15, 848-853.	1.4	215
6	A type I interferon signature in monocytes is associated with poor response to interferon-Î² in multiple sclerosis. Brain, 2009, 132, 3353-3365.	3.7	186
7	Factors related with treatment adherence to interferon b and glatiramer acetate therapy in multiple sclerosis. Multiple Sclerosis Journal, 2005, 11, 306-309.	1.4	184
8	Plasma osteopontin levels in multiple sclerosis. Journal of Neuroimmunology, 2005, 158, 231-239.	1.1	171
9	MAGNIMS consensus recommendations on the use of brain and spinal cord atrophy measures in clinical practice. Nature Reviews Neurology, 2020, 16, 171-182.	4.9	150
10	Transcription-Based Prediction of Response to IFNÎ² Using Supervised Computational Methods. PLoS Biology, 2004, 3, e2.	2.6	144
11	Neurofilament light chain and oligoclonal bands are prognostic biomarkers in radiologically isolated syndrome. Brain, 2018, 141, 1085-1093.	3.7	115
12	Assessment of different treatment failure criteria in a cohort of relapsing-remitting multiple sclerosis patients treated with interferon Î²: Implications for clinical trials. Annals of Neurology, 2002, 52, 400-406.	2.8	114
13	Predicting responders to therapies for multiple sclerosis. Nature Reviews Neurology, 2009, 5, 553-560.	4.9	114
14	COVIDâ€19 in multiple sclerosis patients: susceptibility, severity risk factors and serological response. European Journal of Neurology, 2021, 28, 3384-3395.	1.7	111
15	Is optic neuritis more benign than other first attacks in multiple sclerosis?. Annals of Neurology, 2005, 57, 210-215.	2.8	108
16	Relationship between MRI lesion activity and response to IFN-Î² in relapsingâ€“remitting multiple sclerosis patients. Multiple Sclerosis Journal, 2008, 14, 479-484.	1.4	104
17	Genome-wide Scan of 500Â000 Single-Nucleotide Polymorphisms Among Responders and Nonresponders to Interferon Beta Therapy in Multiple Sclerosis. Archives of Neurology, 2009, 66, 972-8.	4.9	104
18	Identification of a Novel Risk Locus for Multiple Sclerosis at 13q31.3 by a Pooled Genome-Wide Scan of 500,000 Single Nucleotide Polymorphisms. PLoS ONE, 2008, 3, e3490.	1.1	99

#	Article	IF	Citations
19	Assessing response to interferon-Î² in a multicenter dataset of patients with MS. Neurology, 2016, 87, 134-140.	1.5	98
20	The value of oligoclonal bands in the multiple sclerosis diagnostic criteria. Brain, 2018, 141, 1075-1084.	3.7	98
21	A single-center, randomized, double-blind, placebo-controlled study of interferon beta-1b on primary progressive and transitional multiple sclerosis. Multiple Sclerosis Journal, 2009, 15, 1195-1205.	1.4	95
22	Early brain pseudoatrophy while on natalizumab therapy is due to white matter volume changes. Multiple Sclerosis Journal, 2013, 19, 1175-1181.	1.4	93
23	NLRP3 inflammasome is associated with the response to IFN-Î² in patients with multiple sclerosis. Brain, 2015, 138, 644-652.	3.7	93
24	The basal ganglia: a substrate for fatigue in multiple sclerosis. Neuroradiology, 2008, 50, 17-23.	1.1	91
25	Unraveling treatment response in multiple sclerosis. Neurology, 2019, 92, 180-192.	1.5	88
26	Clinical impact of early brain atrophy in clinically isolated syndromes. Multiple Sclerosis Journal, 2013, 19, 1878-1886.	1.4	85
27	Neurofilament light chain level is a weak risk factor for the development of MS. Neurology, 2016, 87, 1076-1084.	1.5	85
28	Fatigue in multiple sclerosis persists over time. Journal of Neurology, 2006, 253, 1466-1470.	1.8	80
29	Spinal cord lesions: A modest contributor to diagnosis in clinically isolated syndromes but a relevant prognostic factor. Multiple Sclerosis Journal, 2018, 24, 301-312.	1.4	79
30	The HLA locus and multiple sclerosis in Spain. Role in disease susceptibility, clinical course and response to interferon-Î². Journal of Neuroimmunology, 2002, 130, 194-201.	1.1	78
31	Pharmacogenomic analysis of interferon receptor polymorphisms in multiple sclerosis. Genes and Immunity, 2003, 4, 147-152.	2.2	77
32	Natural killer cell phenotype and clinical response to interferon-beta therapy in multiple sclerosis. Clinical Immunology, 2011, 141, 348-356.	1.4	72
33	Fatigue in progressive multiple sclerosis is associated with low levels of dehydroepiandrosterone. Multiple Sclerosis Journal, 2006, 12, 487-494.	1.4	67
34	Multiple sclerosis: current treatment algorithms. Current Opinion in Neurology, 2011, 24, 230-237.	1.8	65
35	Disability progression markers over 6â€“12â€‰years in interferon-Î²-treated multiple sclerosis patients. Multiple Sclerosis Journal, 2018, 24, 322-330.	1.4	60
36	Interferon beta in relapsingâ€“remitting multiple sclerosis. Journal of Neurology, 2005, 252, 795-800.	1.8	59

#	Article	IF	Citations
37	Serial diffusion-weighted MR imaging and proton MR spectroscopy of acute large demyelinating brain lesions: case report. American Journal of Neuroradiology, 2002, 23, 989-94.	1.2	56
38	Change in the clinical activity of multiple sclerosis after treatment switch for suboptimal response. European Journal of Neurology, 2012, 19, 899-904.	1.7	55
39	Do multimodal evoked potentials add information to MRI in clinically isolated syndromes?. Multiple Sclerosis Journal, 2010, 16, 55-61.	1.4	54
40	Brain atrophy in natalizumab-treated patients: A 3-year follow-up. Multiple Sclerosis Journal, 2015, 21, 749-756.	1.4	51
41	Menarche, pregnancies, and breastfeeding do not modify long-term prognosis in multiple sclerosis. Neurology, 2019, 92, e1507-e1516.	1.5	49
42	Search for Specific Biomarkers of IFNÎ² Bioactivity in Patients with Multiple Sclerosis. PLoS ONE, 2011, 6, e23634.	1.1	45
43	Interferon Beta-1b for the Treatment of Primary Progressive Multiple Sclerosis. Archives of Neurology, 2011, 68, 1421.	4.9	44
44	Significant clinical worsening after natalizumab withdrawal: Predictive factors. Multiple Sclerosis Journal, 2015, 21, 780-785.	1.4	43
45	Contribution of the symptomatic lesion in establishing MS diagnosis and prognosis. Neurology, 2016, 87, 1368-1374.	1.5	42
46	Proton magnetic resonance spectroscopy in primary and secondary progressive multiple sclerosis. NMR in Biomedicine, 2000, 13, 57-63.	1.6	41
47	Changes in matrix metalloproteinases and their inhibitors during interferon-beta treatment in multiple sclerosis. Clinical Immunology, 2009, 130, 145-150.	1.4	41
48	The long-term outcomes of CIS patients in the Barcelona inception cohort: Looking back to recognize aggressive MS. Multiple Sclerosis Journal, 2020, 26, 1658-1669.	1.4	41
49	Evaluating the response to glatiramer acetate in relapsingâ€“remitting multiple sclerosis (RRMS) patients. Multiple Sclerosis Journal, 2014, 20, 1602-1608.	1.4	36
50	Implication of the tollâ€like receptor 4 pathway in the response to interferonâ€Î²2 in multiple sclerosis. Annals of Neurology, 2011, 70, 634-645.	2.8	35
51	Analysis of prognostic factors associated with longitudinally extensive transverse myelitis. Multiple Sclerosis Journal, 2013, 19, 742-748.	1.4	35
52	Effect of Changes in MS Diagnostic Criteria Over 25 Years on Time to Treatment and Prognosis in Patients With Clinically Isolated Syndrome. Neurology, 2021, 97, e1641-e1652.	1.5	35
53	HLA class I and II alleles and response to treatment with interferon-beta in relapsingâ€“remitting multiple sclerosis. Journal of Neuroimmunology, 2009, 210, 116-119.	1.1	33
54	Specificity of Barkhof Criteria in Predicting Conversion to Multiple Sclerosis When Applied to Clinically Isolated Brainstem Syndromes. Archives of Neurology, 2004, 61, 222.	4.9	32

#	Article	IF	Citations
55	Roles of the ubiquitin peptidase <scp>USP</scp>18 in multiple sclerosis and the response to interferonâ€Î² treatment. European Journal of Neurology, 2013, 20, 1390-1397.	1.7	32
56	Optic Nerve Topography in Multiple Sclerosis Diagnosis. Neurology, 2021, 96, e482-e490.	1.5	32
57	MRI phenotypes with high neurodegeneration are associated with peripheral blood B-cell changes. Human Molecular Genetics, 2016, 25, 308-316.	1.4	31
58	Clinical impact of intravenous methylprednisolone in attacks of multiple sclerosis. Multiple Sclerosis Journal, 2004, 10, 413-416.	1.4	30
59	Predictive value of early brain atrophy on response in patients treated with interferon Î². Neurology: Neuroimmunology and NeuroInflammation, 2015, 2, e132.	3.1	28
60	Plasma chitotriosidase activity in multiple sclerosis. Clinical Immunology, 2009, 131, 216-222.	1.4	27
61	Baseline Gene Expression Signatures in Monocytes from Multiple Sclerosis Patients Treated with Interferon-beta. PLoS ONE, 2013, 8, e60994.	1.1	27
62	Lesion topographies in multiple sclerosis diagnosis. Neurology, 2017, 89, 2351-2356.	1.5	27
63	Clinical characteristics of responders to interferon therapy for relapsing MS. Neurology, 2004, 62, 1653-1653.	1.5	26
64	A 10-year follow-up of the European multicenter trial of interferon Î²-1b in secondary-progressive multiple sclerosis. Multiple Sclerosis Journal, 2016, 22, 533-543.	1.4	24
65	Serum Homocysteine Levels in Multiple Sclerosis. Archives of Neurology, 1994, 51, 1181-1181.	4.9	23
66	Asterixis associated with anatomic cerebral lesions: a study of 45 cases. Acta Neurologica Scandinavica, 1995, 91, 377-381.	1.0	23
67	Induction of serum soluble tumor necrosis factor receptor II (sTNF-RII) and interleukin-1 receptor antagonist (IL-1ra) by interferon beta-1b in patients with progressive multiple sclerosis. Journal of Neurology, 2008, 255, 1136-1141.	1.8	23
68	Risk Acceptance in Multiple Sclerosis Patients on Natalizumab Treatment. PLoS ONE, 2013, 8, e82796.	1.1	23
69	Myelopathy in seronegative SjÃ¶gren syndrome and/or primary progressive multiple sclerosis. Multiple Sclerosis Journal, 2003, 9, 256-259.	1.4	22
70	Brain Volume Loss During the First Year of Interferonâ€Beta Treatment in Multiple Sclerosis: Baseline Inflammation and Regional Brain Volume Dynamics. Journal of Neuroimaging, 2016, 26, 532-538.	1.0	21
71	Grey matter atrophy is associated with disability increase in natalizumab-treated patients. Multiple Sclerosis Journal, 2017, 23, 556-566.	1.4	21
72	EBV-specific immune responses in patients with multiple sclerosis responding to IFNÎ² therapy. Multiple Sclerosis Journal, 2012, 18, 605-609.	1.4	20

#	Article	IF	Citations
73	Short-term suboptimal response criteria for predicting long-term non-response to first-line disease modifying therapies in multiple sclerosis: A systematic review and meta-analysis. Journal of the Neurological Sciences, 2016, 361, 158-167.	0.3	20
74	MR Imaging in Monitoring and Predicting Treatment Response in Multiple Sclerosis. Neuroimaging Clinics of North America, 2017, 27, 277-287.	0.5	20
75	The frequency and characteristics of MS misdiagnosis in patients referred to the multiple sclerosis centre of Catalonia. Multiple Sclerosis Journal, 2021, 27, 913-921.	1.4	20
76	Clinical features of CIS of the brainstem/cerebellum of the kind seen in MS. Journal of Neurology, 2010, 257, 742-746.	1.8	19
77	Natalizumab discontinuation after PML risk stratification: outcome from a shared and informed decision. Multiple Sclerosis Journal, 2012, 18, 1193-1196.	1.4	19
78	HLA alleles as biomarkers of high-titre neutralising antibodies to interferon-Î² therapy in multiple sclerosis. Journal of Medical Genetics, 2014, 51, 395-400.	1.5	19
79	Pharmacogenomic study in patients with multiple sclerosis. Neurology: Neuroimmunology and NeuroInflammation, 2015, 2, e154.	3.1	19
80	Unconventional therapy in multiple sclerosis. Multiple Sclerosis Journal, 2003, 9, 320-322.	1.4	18
81	Interferons and cognition. Journal of the Neurological Sciences, 2006, 245, 137-140.	0.3	18
82	IL28B polymorphisms are not associated with the response to interferon-beta in multiple sclerosis. Journal of Neuroimmunology, 2011, 239, 101-104.	1.1	18
83	Very early scans for demonstrating dissemination in time in multiple sclerosis. Multiple Sclerosis Journal, 2008, 14, 631-635.	1.4	17
84	Up-regulation of inducible heat shock protein-70 expression in multiple sclerosis patients. Autoimmunity, 2014, 47, 127-133.	1.2	17
85	Varicella-zoster meningovasculitis in a multiple sclerosis patient treated with natalizumab. Multiple Sclerosis Journal, 2018, 24, 358-360.	1.4	17
86	Humoral and Cellular Responses to SARS-CoV-2 in Convalescent COVID-19 Patients With Multiple Sclerosis. Neurology: Neuroimmunology and NeuroInflammation, 2022, 9, e1143.	3.1	17
87	Chitinase 3-like 1 is associated with the response to interferon-beta treatment in multiple sclerosis. Journal of Neuroimmunology, 2017, 303, 62-65.	1.1	16
88	Menopause does not modify disability trajectories in a longitudinal cohort of women with clinically isolated syndrome and multiple sclerosis followed from disease onset. European Journal of Neurology, 2022, 29, 1075-1081.	1.7	16
89	Scoring the 10â€year risk of ambulatory disability in multiple sclerosis: the RoAD score. European Journal of Neurology, 2021, 28, 2533-2542.	1.7	16
90	Simultaneous CMV and Listeria infection following alemtuzumab treatment for multiple sclerosis. Neurology, 2019, 92, 296-298.	1.5	15

#	Article	IF	Citations
91	Interferon-Î²1bin the treatment of multiple sclerosis. Expert Opinion on Pharmacotherapy, 2005, 6, 2877-2886.	0.9	14
92	Peripheral blood non-MAIT CD8+CD161hi cells are decreased in relapsing-remitting multiple sclerosis patients treated with interferon beta. Journal of Neuroimmunology, 2015, 288, 98-101.	1.1	12
93	Serum Neurofilament Levels and PML Risk in Patients With Multiple Sclerosis Treated With Natalizumab. Neurology: Neuroimmunology and NeuroInflammation, 2021, 8, .	3.1	12
94	Blood lymphocyte subsets identify optimal responders to IFN-beta in MS. Journal of Neurology, 2018, 265, 24-31.	1.8	11
95	NLRP3 polymorphisms and response to interferon-beta in multiple sclerosis patients. Multiple Sclerosis Journal, 2018, 24, 1507-1510.	1.4	11
96	Is humoral and cellular response to SARS-CoV-2 vaccine modified by DMT in patients with multiple sclerosis and other autoimmune diseases?. Multiple Sclerosis Journal, 2022, 28, 1138-1145.	1.4	11
97	Should we systematically test patients with clinically isolated syndrome for auto-antibodies?. Multiple Sclerosis Journal, 2015, 21, 1802-1810.	1.4	10
98	Treatment response scoring systems to assess long-term prognosis in self-injectable DMTs relapsingâ€“remitting multiple sclerosis patients. Journal of Neurology, 2022, 269, 452-459.	1.8	10
99	IFN-Î² treatment modulates the CD28/CTLA-4-mediated pathway for IL-2 production in patients with relapsing -remitting multiple sclerosis. Multiple Sclerosis Journal, 2004, 10, 630-635.	1.4	9
100	Serial immunoprecipitation assays for interferon--(IFN)-beta antibodies in multiple sclerosis patients. European Cytokine Network, 2003, 14, 154-7.	1.1	9
101	Activation-induced cell death in T lymphocytes from multiple sclerosis patients. Journal of Neuroimmunology, 2014, 272, 51-55.	1.1	8
102	Serum neurofilament light chain levels predict long-term disability progression in patients with progressive multiple sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2022, 93, 732-740.	0.9	8
103	Plasma levels of 15dâ€PGJ₂ are not altered in multiple sclerosis. European Journal of Neurology, 2009, 16, 1197-1201.	1.7	7
104	Any evident MRI T2 lesion activity should guide change of therapy in multiple sclerosis: No. Multiple Sclerosis Journal, 2015, 21, 132-133.	1.4	7
105	Circulating EZH2-positive T cells are decreased in multiple sclerosis patients. Journal of Neuroinflammation, 2018, 15, 296.	3.1	7
106	Oral contraceptives do not modify the risk of a second attack and disability accrual in a prospective cohort of women with a clinically isolated syndrome and early multiple sclerosis. Multiple Sclerosis Journal, 2022, 28, 950-957.	1.4	7
107	Polyregional and hemispheric syndromes: a study of these uncommon first attacks in a CIS cohort. Multiple Sclerosis Journal, 2007, 13, 731-736.	1.4	6
108	Clinically definite multiple sclerosis after radiological Schilder-like onset. Journal of Neurology, 2003, 250, 871-873.	1.8	5

#	Article	IF	Citations
109	Cellular immune responses in multiple sclerosis patients treated with interferon-beta. Clinical and Experimental Immunology, 2013, 171, 243-246.	1.1	5
110	A pharmacogenetic study implicates NINJ2 in the response to Interferon-Î² in multiple sclerosis. Multiple Sclerosis Journal, 2020, 26, 1074-1082.	1.4	5
111	Impact of COVID-19 pandemic on frequency of clinical visits, performance of MRI studies, and therapeutic choices in a multiple sclerosis referral centre. Journal of Neurology, 2022, 269, 1764-1772.	1.8	5
112	Serial gadolinium-enhanced MRI in acute attack of multiple sclerosis treated with plasma exchange. Journal of Neurology, 2003, 250, 243-244.	1.8	4
113	Interferon beta in secondary progressive multiple sclerosis. Journal of Neurology, 2007, 254, 849-853.	1.8	4
114	Herpes simplex encephalitis in the context of immune checkpoint inhibitors: a complex interplay. Acta Neurologica Belgica, 2022, 122, 823-825.	0.5	3
115	Adding brain volume measures into response criteria in multiple sclerosis: the RÃo-4 score. Neuroradiology, 2021, 63, 1031-1041.	1.1	2
116	Disease modifying therapy switching in relapsing multiple sclerosis: A Delphi consensus of the demyelinating expert group of the Spanish society of neurology. Multiple Sclerosis and Related Disorders, 2022, 63, 103805.	0.9	2
117	Treatment with interferon-beta does not induce anti-nuclear and anti-neuronal serum autoantibodies in multiple sclerosis patients. Journal of Neuroimmunology, 2013, 255, 102-104.	1.1	1
118	Spinal cord grey matter atrophy in Multiple Sclerosis clinical practice. Neuroscience Informatics, 2022, 2, 100071.	2.8	1
119	Reply to D. S. Goodin. Journal of Neurology, 2006, 253, 949-949.	1.8	0
120	Clinical commentary on â€œTwo cases of anaphylactic shock by methylprednisolone in neuromyelitis opticaâ€• Multiple Sclerosis Journal, 2018, 24, 1516-1517.	1.4	0
121	Immunotherapy for people with clinically isolated syndrome or relapsing-remitting multiple sclerosis: treatment response by demographic, clinical, and biomarker subgroups (PROMISE)â€”a systematic review protocol. Systematic Reviews, 2022, 11, .	2.5	0